Bevacizumab injections for severe eye vessel disease in premature babies
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial studies whether an anti–blood vessel medicine (bevacizumab, given by eye injection) can improve the structure of the retina in very premature babies with advanced retinopathy of prematurity. It may help when standard treatments like laser or freezing cannot be used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must have retinopathy of prematurity at stage III, IV, or V.
- Your baby’s doctors must say laser or freezing treatment is not possible for the eye condition.
- Your baby cannot be eligible for laser or cryotherapy (freezing) based on the eye exam.
- The study focuses on structural (physical) eye outcomes, so your baby will need follow-up eye visits.
- You will need to agree to the treatment plan and scheduled eye checks required by the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how often low oxygen levels happen in premature babies when they get eye injections for a serious eye condition. The goal is to understand the risks and make the procedure safer.
This trial tests whether giving propranolol by mouth to certain very premature babies with early eye changes can stop retinopathy of prematurity from getting worse. It may help reduce the need for eye treatments later on.
This study uses pictures to map the tiny blood vessels in an infant’s retina (the back of the eye). It may help researchers better understand how eye blood vessel growth happens in premature babies who need screening for ROP (retinopathy of prematurity).
This study looks at newborn eye exams and genetic information to better understand why some premature infants develop a serious vision problem called ROP. You may be invited because your baby needs routine eye screening or is being moved for specialized eye care.
This trial tests whether giving bevacizumab (a medicine that slows abnormal blood vessel growth) right after vitrectomy (a surgery to remove blood or scar tissue from the eye) can help people with advanced diabetic eye disease. The goal is to improve vision and reduce the need for more treatments.
This study compares two ways of giving the medicine bevacizumab in the eye: into the front part (intracameral) versus deeper inside (intravitreal). It aims to see which approach better controls neovascular glaucoma and helps vision, especially when surgery (trabeculectomy) is needed.
Hear when a new Retinopathy of Prematurity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.